ZIM
ITCI

Zacks Investment Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Zacks Investment Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,569
Closed -$1.12M – 724
2023
Q4 		$1.12M Buy
15,569
+235
+2% +$13.5K 0.01% 366
2023
Q3 		$799K Buy
15,334
+5,237
+52% +$305K 0.01% 402
2023
Q2 		$639K Buy
10,097
+106
+1% +$6.61K 0.01% 428
2023
Q1 		$541K Buy
9,991
+1,128
+13% +$54.5K 0.01% 440
2022
Q4 		$469K Buy
8,863
+377
+4% +$18.9K 0.01% 445
2022
Q3 		$395K Buy
8,486
+1,302
+18% +$68K 0.01% 449
2022
Q2 		$410K Buy
+7,184
New +$407K 0.01% 455

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Zacks Investment Management's ITCI Position: Q1 2024 in Review

Zacks Investment Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2024, closing a stake of 15,569 shares — an estimated $1.12M sold.

Zacks Investment Management first reported a position in ITCI in Q2 2022 and held it in 7 quarters. The position peaked at $1.12M in Q4 2023. 346 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

  • Zacks Investment Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2024 after selling out during the quarter.
  • Zacks Investment Management sold 15,569 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $1.12M.
  • Zacks Investment Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2022 and held it in 7 quarters.
  • Zacks Investment Management's Intra-Cellular Therapies Inc. position peaked at $1.12M in Q4 2023.
  • 346 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on Zacks Investment Management's 13F filing for Q1 2024, filed 15 May 2024.